Last reviewed · How we verify
NCT05388032: SOLVE
Sodium Lowering Vascular Effects Trial
NA trial testing Sodium Reduction Intervention in Endothelial Dysfunction in 256 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Tulane University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 256 |
| Start date | 25 January 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sodium Reduction Intervention
Conditions studied
- Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
- Vascular Stiffness — all drugs for Vascular Stiffness →
- Left Ventricular Hypertrophy — all drugs for Left Ventricular Hypertrophy →
- Left Ventricular Dysfunction — all drugs for Left Ventricular Dysfunction →
Sponsor
Tulane University
Who can join
40 and older, any sex, with Endothelial Dysfunction or Vascular Stiffness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structure and function in those with elevated blood pressure or hypertension. Findings from this study will fill the knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk in addition to blood pressure and could provide further evidence on sodium reduction for the prevention of cardiovascular disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05388032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endothelial Dysfunction
Currently open trials in the same condition.
- NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD · Phase 1, PHASE2 · recruiting
- NCT07422974 — Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer · recruiting
- NCT06419959 — NightWare and Cardiovascular Health in Veterans With PTSD · NA · recruiting
- NCT07227727 — Endothelial Dysfunction After SCI · recruiting
- NCT07227740 — Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury · recruiting
Other Tulane University trials
Trials by the same sponsor.
- NCT04007276 — The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients · Phase 4 · not yet recruiting
- NCT07062406 — Enhancing Diabetes Care by Treating Insomnia · NA · not yet recruiting
- NCT06810739 — The Women's Screening and Self-Testing Program (PROMETA) Study · NA · not yet recruiting
- NCT05197998 — Promoting ColorBRAVE Conversations in Families · NA · suspended
- NCT06261840 — Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05388032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tulane University
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing